Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
November-2016 Volume 14 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November-2016 Volume 14 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Integrated analysis of DNA methylation and RNA‑sequencing data in Down syndrome

  • Authors:
    • Jiantao Zhang
    • Wenli Zhou
    • Ying Liu
    • Nan Li
  • View Affiliations / Copyright

    Affiliations: Department of Colorectal Anal Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Neonatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
  • Pages: 4309-4314
    |
    Published online on: September 26, 2016
       https://doi.org/10.3892/mmr.2016.5778
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Down syndrome (DS) is the most common birth defect in children. To investigate the mechanisms of DS, the present study analyzed the bisulfite‑sequencing (seq) data GSE42144, which was downloaded from the Gene Expression Omnibus. GSE42144 included DNA methylation data of three DS samples and three control samples, and RNA‑seq data of two DS samples and five control samples. The methylated sites in the bisulfite‑seq data were detected using Bismark and Bowtie2. The BiSeq tool was applied to determine differentially methylated regions and to identify adjacent genes. Using the Database for Annotation, Visualization and Integrated Discovery, the functions of the abnormal demethylated genes were predicted by functional enrichment analyses. Differentially expressed genes (DEGs) were then screened using a paired t‑test. Furthermore, the interactions of the proteins encoded by selected genes were determined using the Search Tool for the Retrieval of Interacting Genes, and a protein‑protein interaction (PPI) network was constructed using Cytoscape. A total of 74 CpG regions showed significant differential DNA methylation between the DS and normal samples. There were five abnormal demethylated DNA regions in chromosome 21. In the DS samples, a total of 43 adjacent genes were identified with demethylation in their promoter regions and one adjacent gene was identified with upregulated methylation in its promoter regions. In addition, 584 upregulated genes were identified, including 24 genes with transcriptional regulatory function. In particular, upregulated Runt‑related transcription factor 1 (RUNX1) was located on chromosome 21. Functional enrichment analysis indicated that inhibitor of DNA binding 4 (ID4) was involved in neuronal differentiation and transcriptional suppression. In the PPI network, genes may be involved in DS by interacting with others, including nuclear receptor subfamily 4 group A member 2 (NR4A2)‑early growth response (EGR)2 and NR4A2‑EGR3. Therefore, RUNX1, NR4A2, EGR2, EGR3 and ID4 may be key genes associated with the pathogenesis of DS.

Introduction

Down syndrome (DS) or Down's syndrome, also known as trisomy 21, is an autosomal abnormality induced by an extra copy of chromosome 21 and is the most common birth defect among children worldwide (1,2). Children with DS usually have severe mental retardation (3) and delayed development (4), and are prone to gastrointestinal malformations (5). In children, almost 50% of DS cases are accompanied with congenital heart disease (6), and the risk of developing acute leukemia is 20 times higher than that of the normal population globally (7). In addition, patients with DS generally have shorter life expectancy (8,9).

DS is the most common cause of mental retardation and malformation in newborns. During meiosis, chromosome 21 in the egg does not separate, therefore, an extra copy of chromosome 21 is produced (10). When the sperm and the egg fuse, the embryo has 47 chromosomes, with three copies of chromosome 21 (11). An extra chromosome 21 leads to the overexpression of its genes, causing nerve dysfunction in vivo, and affecting the normal growth and development of children (12). At present, prenatal diagnosis is the optimal approach in preventing DS, however, there are no effective drugs for treatment of the disease. Thus, it is important to investigate the molecular mechanisms of DS.

Previous studies have suggested that the elevated gene expression of human chromosome 21 (HSA21) is responsible for specific aspects of the DS phenotype. Arron et al (13) showed that certain characteristics of the DS phenotype can be associated with the increased expressions of two HSA21 genes, namely those encoding the transcriptional activator, regulator of calcineurin 1 (DSCR1-RCAN1), and the protein kinase, dual-specificity tyrosine phosphorylation-regulated kinase (DYRK)1A. The overexpression of a number of HSA21 genes, including DYRK1a, synaptogenin 1 and single-minded homolog 2, results in learning and memory defects in mouse models, suggesting that trisomy of these genes may contribute to learning disability in patients with DS (14,15).

The abnormal copy number of chromosome 21 is the primary genetic characteristics of DS. Therefore, the present study applied a variety of bioinformatics tools to determine the genetic fragments in chromosome 21. The methylated sites in bisulfite-sequencing (seq) data were detected, differentially methylated regions between DS and control samples were determined, and the adjacent genes of differential DNA methylation regions were identified. Subsequently, the functions of the abnormal demethylated genes were predicted using Gene Ontology (GO) enrichment analyses. The differentially expressed genes (DEGs) between the DS and control samples were screened. Furthermore, the interactions/associations between the proteins encoded by selected genes were determined, and a protein-protein interaction (PPI) network was constructed. The present study aimed to identify the key genes involved in DS, and may be able to establish the theoretical foundation for the targeted therapy of DS.

Materials and methods

Data sources

The bisulfite-seq data GSE42144 deposited by Jin et al (16) was downloaded from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) of the National Center for Biotechnology Information, which was based on the platform of the Illumina Genome Analyzer IIx (Illumina, Inc., San Diego, CA, USA). GSE42144 included three placental samples (GSM1032059, GSM1032060 and GSM1032061) from patients with DS and three normal control samples (GSM1032070, GSM1032071 and GSM1032072). According to the quality control results of RNA-seq data, two RNA-seq data from patients with DS (GSM1033476 and GSM1033478) and five RNA-seq data from normal control samples (GSM1033470, GSM1033471, GSM1033472, GSM1033473 and GSM1033474) were also used in the present study.

Alignment of bisulfite-seq data and detection of DNA methylation

For all bisulfite-seq data, Bismark (www.bioinformatics.bbsrc.ac.uk/projects/bismark/) (17) and Bowtie 2 (bowtie-bio.sourceforge.net/bowtie2/index.shtml) (18) software were applied to perform read alignment, analyze methylated DNA signaling and output cytosine methylation sites in the genome. All parameters were set at default values.

Differential DNA methylation and corresponding adjacent gene analysis

The BiSeq tool (19) was used to determine differentially methylated regions between the placenta samples of patients with DS and normal control samples. The false discovery rate of each significant differentially methylated CpG cluster was ≤0.1. The methylated CpG clusters with a length of <100 bp were merged and defined as a differentially methylated DNA region. In addition, the length of each differentially methylated DNA region was required to be ≥50 bp. If the distance between the center of the differentially methylated DNA region and the transcription start site of a specific gene ranged between 3,000 and 500 bp, the differentially methylated DNA region was considered to have the potential to affect the gene, and this gene was defined as an adjacent gene of the differentially methylated DNA region.

Alignment of RNA-seq data and calculation of gene expression

Tophat (4) software was used to perform read alignment, with the University of California Santa Cruz (genome.ucsc.edu) hg19 genome sequences as a reference. For read alignment, up to two base mismatches were permitted in one read. Only the reads which mapped to specific genome locations were retained for further analysis. The other parameters were set to the defaults. On combining with the Refseq gene annotations, the transcripts were assembled and gene expression values were calculated using Cufflinks and Cuffdiff tools (5). The calculated gene expression values were based on the fragments per kilobase of transcript per million fragments mapped method (20).

Analysis of DEGs

The paired t-test (21) was used to identify DEGs between the DS and control samples. P<0.01 and |log2fold-change|≥2 were used as the cut-off criteria.

Function annotation of the adjacent genes

The Database for Annotation, Visualization, and Integrated Discovery (22) was used to perform GO enrichment analysis for the adjacent genes of the differentially methylated DNA regions. The GO terms were classified into biological process, molecular function and cellular component categories. P<0.05 was used as the cut-off criterion.

PPI network construction

The interaction associations of the proteins encoded by selected genes were determined using the Search Tool for the Retrieval of Interacting Genes (STRING) database (23). All parameters were set to defaults. A PPI network was then constructed using Cytoscape (24).

Results

Identification of differential DNA methylation regions in DS

Based on the Bisulfite-seq data, a total of 74 CpG regions had significant differential DNA methylation between the DS and normal samples, including 68 demethylated regions, accounting for 92%, and six regions with higher levels of methylation, compared with those of the normal samples.

For a single chromosome, the majority of the abnormal DNA methylation regions were detected in chromosomes 7 and 17, showing a total of seven aberrantly methylated DNA regions. In chromosome 21, five abnormal demethylated DNA regions were found (Fig. 1).

Figure 1.

Distribution of differentially methylated DNA regions in each chromosome. Blue indicates hypomethylated DNA regions and red indicates hypermethylated DNA regions. DS, Down syndrome; chr, chomosome.

Identification of adjacent genes of the differentially methylated DNA

Compared with the control samples, a total of 43 adjacent (protein-coding) genes were identified in the DS samples with demethylated promoter regions and one adjacent gene, chromosome 19 open reading frame 80, which is known to be located in chromosome 19, was identified with upregulated methylation in its promoter region (Table I).

Table I.

Number of adjacent genes with differentially methylated DNA regions in Down syndrome samples.

Table I.

Number of adjacent genes with differentially methylated DNA regions in Down syndrome samples.

MethylationProtein-coding genes (n)Noncoding genes (n)
Hypomethylated430
Hypermethylated  10

In the autosomal chromosomes, there were six DS-associated genes with demethylated promoter regions in chromosome 17. The number of abnormal genes in other chromosomes ranged between one and three. No genes were found to be affected by abnormal DNA demethylation in the sex chromosomes.

The distributions of the genes on chromosomes are listed in Table II. Among these, only Runt-related transcription factor 1 (RUNX1) was found to be located on chromosome 21, and the demethylation of the promoter region of this gene was significant (Table II).

Table II.

Distribution of adjacent genes with demethylated regions in DS sample chromosomes.

Table II.

Distribution of adjacent genes with demethylated regions in DS sample chromosomes.

ChromosomenGene
  12LOC730144, EIF1
  23ATG4B, LRRFIP1, STRADB
  31EXOG
  41FRYL
  53BOD1, B4GALT7, BRD9
  62MAP3K4, ID4
  74PAXIP1, POLM, FAM131B, AGAP3
  82ATAD2, REEP4
  92BARX1, KIAA1539
102OTUD1, GPRIN2
111SLC1A2
121ALDH2
133HMGB1, HMGB1L10, FARP1
141RTN1
152TYRO3, PCSK6
161FA2H
176UTP18, LOC730144, C17ORF56, EIF1, TIMP2, MRM1
181ABHD3
202CBFA2T2, C20ORF20
211RUNX1
223HMGB1, OSBP2, HMGB1L10
Functional enrichment of abnormal demethylated genes

The present study subsequently analyzed the functions of the 43 abnormally demethylated genes. Combined with GO functional annotation, the five genes, high mobility group box (HMGB)1, HMGB1L10, inhibitor of DNA binding 4 (ID4), leucine-rich repeat flightless-interacting protein 1 and core-binding factor, Runt domain, α subunit 2; translocated to, 2 (CBFA2T2) were found to be involved in the biological process of negative regulation of transcription, whereas the three genes, BARX homeobox 1, DNA polymerase mu and RUNX1, were associated with immune system development. In addition, the present study found that solute carrier family 1 member 2, ID4 and tissue inhibitor of matrix metalloproteinase 2 were predominantly involved in forebrain development and regulation of neurogenesis. The HMGB1, HMGB1L10, ID4, RUNX1 and CBFA2T2 genes possessed the capabilities of transcription factor binding, according to the molecular function terms (Table III).

Table III.

Functional annotation of the adjacent genes with demethylated promoter regions in Down syndrome samples.

Table III.

Functional annotation of the adjacent genes with demethylated promoter regions in Down syndrome samples.

CategoryGO termGenes (n)Gene
BPGO:0016481~negative regulation of transcription5HMGB1, HMGB1L10, ID4, LRRFIP1, CBFA2T2
BPGO:0002520~immune system development3BARX1, POLM, RUNX1
BP GO:0032147~activation of protein kinase activity2MAP3K4, STRADB
BP GO:0030855~epithelial cell differentiation2BARX1, CBFA2T2
BP GO:0030900~forebrain development2SLC1A2, ID4
BP GO:0050767~regulation of neurogenesis2ID4, TIMP2
CC GO:0005694~chromosome4HMGB1, BOD1, BARX1, HMGB1L10
CC GO:0019898~extrinsic to membrane3OSBP2, PCSK6, FARP1
MF GO:0008134~transcription factor binding5HMGB1, HMGB1L10, ID4, RUNX1, CBFA2T2
MF GO:0016564~transcription repressor activity3ID4, LRRFIP1, CBFA2T2
MF GO:0030528~transcription regulator activity6BARX1, ATAD2, ID4, LRRFIP1, RUNX1, CBFA2T2

[i] GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function.

Functional enrichment analysis showed that ID4 was not only involved in neuronal differentiation, but also functioned in transcriptional suppression. The demethylation of its promoter region led to the increased expression level of ID4 (Table III).

Analysis of DEGs

Combined with the RNA-seq data, the present study analyzed transcriptome differences between the DS samples and normal samples, and identified a total of 584 DEGs, including RUNX1, which were upregulated (Table IV).

Table IV.

Number of differentially expressed genes in Down syndrome samples, compared with control samples.

Table IV.

Number of differentially expressed genes in Down syndrome samples, compared with control samples.

ExpressionGenes (n)Transcription factors (n)
Upregulated58424
Downregulated  0  0

Based on the detection of tissue-specific gene database, 208 of the 584 DEGs (36%) were found to have specific expression in brain tissue. By contrast, 52 DEGs in the DS samples were expressed specifically in neutrophils, the pituitary, peripheral nervous system, stomach and T-cells, which was substantially lower than the number of brain tissue-specific genes (Fig. 2).

Figure 2.

Distribution of tissue-specific differentially expressed genes in Down syndrome samples.

Finally, with the addition of transcription factor data, the present study identified 24 DEGs with transcriptional regulatory function, of which the eight transcription factors, zinc finger protein 43, early growth response (EGR)3, nuclear receptor subfamily 4, group A, member 2 (NR4A2), nuclear receptor subfamily 3, group C, member 2 (NR3C2), LIM homeobox 2, gastrulation brain homeobox 2, pentraxin-related gene, rapidly induced by interleukin-1β and nuclear factor I/A, were brain-tissue specific (Table V).

Table V.

Differentially expressed genes with transcriptional regulatory function and brain tissue specificity.

Table V.

Differentially expressed genes with transcriptional regulatory function and brain tissue specificity.

Transcription factorDescriptionBrain-specific
ZNF43Zinc finger protein 43Yes
EGR3Early growth response 3Yes
EGR2Early growth response 2No
ZFYZinc finger protein, Y-linkedNo
MITF Microphthalmia-associated transcription factorNo
NR4A2Nuclear receptor subfamily 4, group A, member 2Yes
NR3C2Nuclear receptor subfamily 3, group C, member 2Yes
FOXN1Forkhead box N1No
HOXB13Homeobox B13No
VAX2Ventral anterior homeobox 2No
HNF4GHepatocyte nuclear factor 4, γNo
SIX4SIX homeobox 4No
FOXP1Forkhead box P1No
HESX1HESX homeobox 1No
ERCC8Excision repair cross-complementing rodent repair deficiency, complementation group 8No
HOXA1Homeobox A1No
HOXB5Homeobox B5No
LHX2LIM homeobox 2Yes
PAX8Paired box 8No
GBX2Gastrulation brain homeobox 2Yes
LHX6LIM homeobox 6No
PTX3Pentraxin-related gene, rapidly induced by IL-1βYes
NFIANuclear factor I/AYes
NFIBNuclear factor I/BNo
Association between differential methylation and dysregulation

In order to examine the potential link between abnormal methylation and dysregulation in DS samples, the present study integrated their data combined with protein-protein interactions the STRING database, and found only one PPI network (Fig. 3). The network contained five genes, including NR4A2, EGR2, EGR3, RUNX1 and hepatocyte nuclear factor 4, γ (HNF4G). There were several interactions, including RUNX1-NR4A2, NR4A2-EGR2 and NR4A2-EGR3, in the PPI network.

Figure 3.

Motif analyses between the genes with demethylated DNA in promoter regions and DEGs in DS samples. Red nodes represent significantly upregulated genes and the orange node represents a moderately upregulated gene. The V-node represents the gene in which the promoter region was significantly demethylated, and circle nodes indicate the genes without significantly altered methylation. The blue lines indicate protein-protein interactions. RUNX1, Runt-related transcription factor 1; NR4A2 nuclear receptor subfamily 4 group A member 2; EGR, early growth response; HNF4G hepatocyte nuclear factor 4, γ.

Discussion

As a genetic disease in which an individual has 47 chromosomes instead of the usual 46 (25), DS affects ~1/730 live births and occurs in all populations equally (26). In the present study, bioinformatics tools were used to determine the genetic fragments associated with DS. A total of 74 CpG regions had significant differential DNA methylation between the DS and normal samples. There were five abnormal DNA demethylated regions in chromosome 21. A total of 43 adjacent genes with demethylation in promoter regions and one adjacent gene with upregulated methylation in promoter regions were identified in the DS samples. In addition, 584 upregulated genes were identified, including 24 genes with transcriptional regulatory function. Only NR4A2, EGR2, EGR3, RUNX1 and HNF4G were involved in the PPI network.

In the present study, upregulated RUNX1 was located on chromosome 21, and the demethylation of the promoter region of this gene was significant. Functional enrichment analysis showed that RUNX1 was associated with immune system development and possessed the capabilities of transcription factor binding. It is reported that the expression of RUNX1 in megakaryoblasts in children with DS and acute megakaryocytic leukemia is lower, compared with cases of acute megakaryocytic leukemia without DS (27,28). The risk of developing dementia of Alzheimer's disease in individuals with DS is higher, compared with that of the general population, and a variant within RUNX1 is closely linked with dementia of Alzheimer's disease in DS (29). A previous study reported that RUNX1 and NR4A2 can coordinately regulate the differentiation of T cells (30,31). The transcription factor, NURR1, which is also known as NR4A2, is important in the functional maintenance, development and survival of midbrain dopaminergic neurons (32). As with DS, Parkinson's disease is also a disorder of the central nervous system, and decreased expression levels of NURR1 may contribute to the identification of Parkinson's disease and other neurlogical disorders (33). The transcription factors, EGR2 and EGR3, are members of the Egr family, which is involved in regulating the peripheral immune response, and EGR2 may serve as a potential target in neuroinflammation therapy for its host defense role in the central nervous system immune response (34). According to the results of the present study, transcription factors EGR3 and NR4A2 were identified as brain-tissue specific. In the PPI network, several interactions were identified, including RUNX1-NR4A2, NR4A2-EGR2 and NR4A2-EGR3, indicating that RUNX1 and NR4A2 may be involved in DS by coordinately regulating EGR2 and EGR3.

As a member of the ID family, ID4 inhibits the differentiation or the DNA binding of basic helix-loop-helix transcription factors, regulating genes, which are important in neuronal differentiation (35). A previous study demonstrated that ID1, ID2, ID3 and ID4 are promising primary targets for methyl-CpG binding protein 2-regulated neuronal maturation, which may be responsible for the development of Rett syndrome, a neurodevelopmental disorder (36). In the present study, functional enrichment analysis indicated that ID4 possessed the capabilities of transcription factor binding, and that ID4 was involved in neuronal differentiation and transcriptional suppression. Therefore, it was hypothesized that the upregulated expression level of ID4 may be associated with the symptoms of severe mental retardation and stunting of the nervous system, which are observed in patients with DS.

In conclusion, the present study performed integrated bioinformatics analyses of DNA methylation and RNA-seq data to identify genes, which may be correlated with DS. A total of 43 adjacent genes with demethylation of promoter regions and one adjacent gene with upregulated methylation of its promoter region were identified in the DS samples. In addition, 584 upregulated genes were identified, which included 24 genes with transcriptional regulatory function. RUNX1, NR4A2, EGR2, EGR3 and ID4 may be correlated with DS. However, their mechanisms of action in DS remain to be fully elucidated and further experimental validation is required.

References

1 

Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Deciu C, Grody WW, et al: DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet Med. 13:913–920. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Grody WW, et al: DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: An international collaborative study. Genet Med. 14:296–305. 2012. View Article : Google Scholar : PubMed/NCBI

3 

Khocht A, Yaskell T, Janal M, Turner BF, Rams TE, Haffajee AD and Socransky SS: Subgingival microbiota in adult Down syndrome periodontitis. J Periodontal Res. 47:500–507. 2012. View Article : Google Scholar : PubMed/NCBI

4 

Rosdi M, Kadir A, Sheikh RS, Hj Murat Z and Kamaruzaman N: The comparison of human body electromagnetic radiation between down syndrome and non down syndrome person for brain, chakra and energy field stability score analysis. 2012 IEEE Control and System Graduate Research Colloquium. Malaysia. pp. 370–375. 2012;

5 

Ward O: John Langdon Down: The man and the message. Downs Syndr Res Pract. 6:19–24. 1999. View Article : Google Scholar : PubMed/NCBI

6 

Cronk C, Crocker AC, Pueschel SM, Shea AM, Zackai E, Pickens G and Reed RB: Growth charts for children with Down syndrome: 1 month to 18 years of age. Pediatrics. 81:102–110. 1988.PubMed/NCBI

7 

Myrelid A, Gustafsson J, Ollars B and Annerén G: Growth charts for Down's syndrome from birth to 18 years of age. Arch Dis Child. 87:97–103. 2002. View Article : Google Scholar : PubMed/NCBI

8 

Lott IT: Neurological phenotypes for Down syndrome across the life span. Prog Brain Res. 197:1012012. View Article : Google Scholar : PubMed/NCBI

9 

Roizen NJ and Patterson D: Down's syndrome. Lancet. 361:1281–1289. 2003. View Article : Google Scholar : PubMed/NCBI

10 

Freeman SB, Bean LH, Allen EG, Tinker SW, Locke AE, Druschel C, Hobbs CA, Romitti PA, Royle MH, Torfs CP, et al: Ethnicity, sex, and the incidence of congenital heart defects: A report from the national down syndrome project. Genet Med. 10:173–180. 2008. View Article : Google Scholar : PubMed/NCBI

11 

Hernandez D and Fisher EM: Down syndrome genetics: Unravelling a multifactorial disorder. Hum Mol Genet. 5:1411–1416. 1996.PubMed/NCBI

12 

Patterson D and Costa AC: Down syndrome and genetics-a case of linked histories. Nat Rev Genet. 6:137–147. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Arron JR, Winslow MM, Polleri A, Chang CP, Wu H, Gao X, Neilson JR, Chen L, Heit JJ, Kim SK, et al: NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature. 441:595–600. 2006. View Article : Google Scholar : PubMed/NCBI

14 

Altafaj X, Dierssen M, Baamonde C, Martí E, Visa J, Guimerà J, Oset M, González JR, Flórez J, Fillat C and Estivill X: Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum Mol Genet. 10:1915–1923. 2001. View Article : Google Scholar : PubMed/NCBI

15 

Voronov SV, Frere SG, Giovedi S, Pollina EA, Borel C, Zhang H, Schmidt C, Akeson EC, Wenk MR, Cimasoni L, et al: Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndrome. Proc Natl Acad Sci USA. 105:9415–9420. 2008. View Article : Google Scholar : PubMed/NCBI

16 

Jin S, Lee YK, Lim YC, Zheng Z, Lin XM, Ng DP, Holbrook JD, Law HY, Kwek KY, Yeo GS and Ding C: Global DNA hypermethylation in down syndrome placenta. PLoS Genet. 9:e10035152013. View Article : Google Scholar : PubMed/NCBI

17 

Krueger F and Andrews SR: Bismark: A flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics. 27:1571–1572. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Langmead B, Trapnell C, Pop M and Salzberg SL: Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10:R252009. View Article : Google Scholar : PubMed/NCBI

19 

Hebestreit K, Dugas M and Klein HU: Detection of significantly differentially methylated regions in targeted bisulfite sequencing data. Bioinformatics. 29:1647–1653. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Mortazavi A, Williams BA, McCue K, Schaeffer L and Wold B: Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 5:621–628. 2008. View Article : Google Scholar : PubMed/NCBI

21 

Hsu H and Lachenbruch PA: Paired t test. Wiley Encyclopedia of Clinical Trials. 1–3. 2008.

22 

Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC and Lempicki RA: DAVID bioinformatics resources: Expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 35:(Web Server issue). W169–W175. 2007. View Article : Google Scholar : PubMed/NCBI

23 

Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, et al: STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 37:(Database issue). D412–D416. 2009. View Article : Google Scholar : PubMed/NCBI

24 

Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, Pico AR, Bader GD and Ideker T: A travel guide to Cytoscape plugins. Nat Methods. 9:1069–1076. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A, Ginsberg SD, Cataldo AM, Mathews PM and Nixon RA: Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci USA. 107:1630–1635. 2010. View Article : Google Scholar : PubMed/NCBI

26 

van Gameren-Oosterom H, Fekkes M, van Wouwe JP, Detmar SB, Oudesluys-Murphy AM and Verkerk PH: Problem behavior of individuals with Down syndrome in a nationwide cohort assessed in late adolescence. J Pediatr. 163:1396–1401. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, Baruchel A, Cavé H, Dastugue N, Hasle H, et al: Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci USA. 103:3339–3344. 2006. View Article : Google Scholar : PubMed/NCBI

28 

Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, Boerner JL, Taub JW, Matherly LH and Ge Y: RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: Role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood. 114:2744–2752. 2009. View Article : Google Scholar : PubMed/NCBI

29 

Patel A, Rees SD, Kelly MA, Bain SC, Barnett AH, Thalitaya D and Prasher VP: Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome. Neurosci Lett. 487:144–148. 2011. View Article : Google Scholar : PubMed/NCBI

30 

Sekiya T, Kashiwagi I, Inoue N, Morita R, Hori S, Waldmann H, Rudensky AY, Ichinose H, Metzger D, Chambon P and Yoshimura A: The nuclear orphan receptor Nr4a2 induces Foxp3 and regulates differentiation of CD4+ T cells. Nat Commun. 2:2692011. View Article : Google Scholar : PubMed/NCBI

31 

Okada M, Hibino S, Someya K and Yoshmura A: Regulation of regulatory T cells: Epigenetics and plasticity. Adv Immunol. 124:249–273. 2014. View Article : Google Scholar : PubMed/NCBI

32 

Jankovic J, Chen S and Le WD: The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 77:128–138. 2005. View Article : Google Scholar : PubMed/NCBI

33 

Le W, Pan T, Huang M, Xu P, Xie W, Zhu W, Zhang X, Deng H and Jankovic J: Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci. 273:29–33. 2008. View Article : Google Scholar : PubMed/NCBI

34 

Yan Y, Tan X, Wu X, Shao B, Wu X, Cao J, Xu J, Jin W, Li L, Xu W, et al: Involvement of early growth response-2 (Egr-2) in lipopolysaccharide-induced neuroinflammation. J Mol Histol. 44:249–257. 2013. View Article : Google Scholar : PubMed/NCBI

35 

Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE and Hoon DS: Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene. 24:4721–4727. 2005. View Article : Google Scholar : PubMed/NCBI

36 

Peddada S, Yasui DH and LaSalle JM: Inhibitors of differentiation (ID1, ID2, ID3 and ID4) genes are neuronal targets of MeCP2 that are elevated in Rett syndrome. Hum Mol Genet. 15:2003–2014. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Zhang J, Zhou W, Liu Y and Li N: Integrated analysis of DNA methylation and RNA‑sequencing data in Down syndrome. Mol Med Rep 14: 4309-4314, 2016.
APA
Zhang, J., Zhou, W., Liu, Y., & Li, N. (2016). Integrated analysis of DNA methylation and RNA‑sequencing data in Down syndrome. Molecular Medicine Reports, 14, 4309-4314. https://doi.org/10.3892/mmr.2016.5778
MLA
Zhang, J., Zhou, W., Liu, Y., Li, N."Integrated analysis of DNA methylation and RNA‑sequencing data in Down syndrome". Molecular Medicine Reports 14.5 (2016): 4309-4314.
Chicago
Zhang, J., Zhou, W., Liu, Y., Li, N."Integrated analysis of DNA methylation and RNA‑sequencing data in Down syndrome". Molecular Medicine Reports 14, no. 5 (2016): 4309-4314. https://doi.org/10.3892/mmr.2016.5778
Copy and paste a formatted citation
x
Spandidos Publications style
Zhang J, Zhou W, Liu Y and Li N: Integrated analysis of DNA methylation and RNA‑sequencing data in Down syndrome. Mol Med Rep 14: 4309-4314, 2016.
APA
Zhang, J., Zhou, W., Liu, Y., & Li, N. (2016). Integrated analysis of DNA methylation and RNA‑sequencing data in Down syndrome. Molecular Medicine Reports, 14, 4309-4314. https://doi.org/10.3892/mmr.2016.5778
MLA
Zhang, J., Zhou, W., Liu, Y., Li, N."Integrated analysis of DNA methylation and RNA‑sequencing data in Down syndrome". Molecular Medicine Reports 14.5 (2016): 4309-4314.
Chicago
Zhang, J., Zhou, W., Liu, Y., Li, N."Integrated analysis of DNA methylation and RNA‑sequencing data in Down syndrome". Molecular Medicine Reports 14, no. 5 (2016): 4309-4314. https://doi.org/10.3892/mmr.2016.5778
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team